Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who can I sell to at .10?
You went from 0.005 to 0.10???!!!
Do you mean a second financing after the uplist? That would make sense. On a fully diluted basis the market cap at a .10 equivalent is probably higher than $90M.
Back to CUBT. I had a conversation (emails) today with one of my contacts in the small and large cap world this afternoon. Not a penny stock promoter but a person who helps to bring in accredited investors to SPACS, RM's, and IPO's.
He was familiar with CUBT but not involved financially.
Basic gist is he understands a finance deal done with about a 5 x valuation from .02 is going to happen once it reaches that point. So .10. . ($90 M market cap) After that he said it is up the company to deliver. Which is always a crapshoot with bio's.
Take that for what it is.
The CUBT longs are probably time fatigued. I know this long is, LOL. Not a whole lot to talk about until their plan actually has some $ behind it which hopefully we are closer to with the filing of the S1. And we shall see if they are actually able to execute it this time around.
And btw I still stick by what I said. Look at any S1 terms either here on the OTC or the NASDAQ. No initial angel or accredited investors pay full price for a stock. They get a discount and that is 99.9999999999999% of the time. Usually anywhere from 40 to 70% of the share price based on a specific date. It is the risk they take for investing in a company without an opportunity to sell right away. Hence the discount.
For example, with standard stock offerings or an S1 (for example DJT in April) they get a discount and normally the price tanks. Happens almost all the time every time. That sank to the low $20s after but has since recovered and went above $50 last week. But again, they cannot sell until later in Sept of this year. Hence the reason why they get a discount. It is like having your money in a bank for 6 months and you can't take it out.
It is VERY normal. And the selloff is as well. And many times the stock recovers. Obviously if CUBT can even deliver on half of what they say the stock has a $200 M valuation at the min. But again, the market has to believe it.
I agree with all of that and believed it. I was saying that .005 based on the moderate selling pressure but more importantly the zero bid support.
It was as if all CUBT longs went on strike.
Happy to be wrong. At least for right now.
On 5/9 you said a stock price of .06 was very reasonable and the terms of the S1 looked relatively good compared to other OTC stocks.
The S1 had stated a $4 offering price post split which is .01 now. I am trying to understand how you first reached a current .06 valuation. I’d love to see it but it is not surprising that the stock price has migrated toward the .01 offering price. That seems logical to me. No one is going to buy this stock now for anywhere near .06 with a pending .01 offering.
It takes volume to move a stock and there just hasn’t been any new investors or volume on a daily basis for two years, especially given their OS number of what 700M shares or whatever it is. I blame the company for that for a lack of communication and for missing prior targets.
Now you are saying you expect the price in the .005 range. Why the wild fluctuations when you thought the terms were right and thought a .06 was reasonable? Unless you thought your opinion of the price today would actually move the stock which is not going to happen. Nothing substantial will happen here until they uplist and get financing. My only hope is that they have an IR communication plan in place. Because if they uplist and continue to not communicate and sit on their hands like they have been for two years then the market makers will drive this thing down under $1.
.005s this week.
Based on how quiet the pro longs here are.....either they all sold out or got word that bad news is imminent.
Yes. Investors are saying why give these insiders a 100% return at .01 when the stock was at .02ish at the time?
It makes no sense. Take the stock down to .005 or lower and make these guys actually do something.
Which they won't.
You mean before S1go in effect?
At this rate it will be under .01 by early next week. .005s looks imminent.
Retail investors are always screwed
this situations
After if they do the reverse split and I'm blast, it's going to go from $4 to $0.20 in the blink of an eye
Lots of people bought over .02 the past 6 months. 10s of millions of shares. Only a milly or two took this down under .015.
There is no pro CUBTers left
Where are the pro CUBT'ers? They have been pretty quiet lately.
Deep shit
Amazing. All that buying up to the mid .03s for the past 6 months demolished in 3 days. I can't imagine the buyers who bought all of the millions of shares over .02 are very happy.
Student of the game IR Steve.....any comment?
Insiders are always going to get a discount. Very common in financing deals. So the S1 itself is not unusual.
However obviously investors hate it.
I don't know that that is the case. I think it is hard for folks to buy st .02 etc. when the offering is st .01. I suspect we will stay in this range until the using at which point, hopefully, we start getting news. With insiders having a lock-up, they have every incentive to update shareholders and increase the share price.
Disappointing to say the least. Obviously the market did not like the S1.
Sad to say but this appears to be headed back to .01. Zero bid support.
I’ve been warning all of you that this is a scam Richard Barry Paul, all live in high on the hog off of your hard earned money with nothing at all to show for it zero zilch I would sell take this back to a worthless stock. make them worthless SOBs get a job
Where’s Garr? Where is any leader of CUBT at?
Good move for you. Some people do not have the ability to trade microcaps. Managing risk is just as important as picking the stock. You have to able to sell stock at different price points and realize you sold "too soon".
Good luck on your next investment. Remember, "rent" these stocks, do not buy them. LOL
I’m not buying this shit back why so I can sit on it for another four years and watch nothing happened lol
Very clever. Time to sell...so you can buy at the lows.
Smart....like selling 1/2 of your position when up 500%
But...maybe my memory is wrong.
This company is a scam. Everybody here should cut their losses and put this company and the scam management out of their misery. The only thing that keeps the scam going is people staying invested it’s never going to do anything it’s been four years with not 1 ounce of progress.
Oh I forgot a few
Why invest? Buy at 4. Sell at 7-8 that’s a 75-100% return. Not too bad
You’re not supposed to interact with me. Please stop
They going to start now looking for investors. Do you really think that it's going to be any investors who want to invest in this company or not? I am surprised that he didn't drop to 0.01 after S1 was released.
I mean that would entail all of the investors selling before the company even initiated progress on their drug port. Which makes no sense. Otherwise why even invest in CUBT? Obviously they have 'stuff' coming. And even if it does drop to .01. Who cares? It has been at .01 for 2 years. That isn't a new thing.
People get in this for a 1000% gain or more.
And......
Again.....no warrants.
So you don't expect it to drop by at least 200% from $4 to like $1?
Agree. I am a big critic of the company but these S1 terms are fairly standard and actually better than many OTC stocks trying to do the same thing that I have seen. I see no problem with it.
In fact I have seen many otc companies having to let shares be given away to investors at .001 when the stock is at .05 or more. So the fact that this is at .01 with no warrants? Again no warrants....I think that is EXTREMELY FAIR to all. That is not a critique worth anything here.
I can only hazard a guess that since CUBT looks as though they have this S1 ready to go and getting approved? That their drug pipeline and future plans are in agreement with the investors that they have lined up.
I am not saying that this stock should be at 20 cents right now, but based on the OS and the potential revs that 'could happen'? A 6 cent valuation is very reasonable. Which only gives this a $45 M valuation. Which is very very fair considering the drug potential.
It is going to collapse big time. I assume about 300%
Insiders have been given themselves shares for a long time. What we have been saying about this setup is those “investors “ in the offering are not locked up. They buy at 4 sell at 7-8. The selling pressure will sink the pps how far I don’t know but as student pointed out the whole idea of the offering is to raise a few bucks to get the drug to trial and uplist.
Why do you think the pps will not collapse post RS? I’m looking for anything positive
And you know it? Or you just speculating?
I don't know how people are acting surprised by the S1. The terms are fairly standard and ultimately much better for shareholders than convertible notes in the OTC world. Insiders have a 6 month lock-up and will have every incentive to see the company appreciate in value. Additionally, the lack of warrants should increase the likelihood that any institution partaking in the offering holds their shares opposed to selling them and riding the warrants for free for upside. The stock will trade very thinly and be volatile. This is and always has been a high-risk investment with large upside and the risk of significant losses. That all being said, if we complete the uplist, the chances of reaching the large upside should increase meaningfully.
All of us the common shareholders going to be screwed after uplist Anyway, it will take another 3 to 5 years and maybe something will be achieved by this company. No one is able to sell anything unless they sell it for 0.005. oh well
Animal studies are obviously only to prove safety and, as far as I know only humans develop AMD. Clearly if CUBT is moving forward and planning human trials then the animal trials must have shown the safety in animals.
Remember that Metformin has been prescribed as a first line treatment for type 2 diabetes since 1995. CUBT is using Metformin in a topical eye solution.
Student, what were the final results on the animal test? Was the results better than expected? In your opinion, have you talked to any big money about investing after the uplist?
OTC: CUBT http://CurativeBiotech.com INVESTOR PRESENTATION https://curativebiotech.com/news-and-media/presentations Curative Biotechnology, a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop an adjuvant for the COVID-19 vaccines which enhance antibody response. Current Drug Pipeline https://curativebiotech.com/pipelineTreatments for six (6) Ocular conditions, one (1) Oncology, one (1) Infectious disease and one (1) vaccine adjunct candidate* Metformin eyedrops for treatment of Acute Macular Degeneration (AMD) AMD is a visually threatening condition, most often found in patients over age 60. Early and Intermediate AMD are characterized by enlarged drusen behind the eye’s retina. Close to 10% of the world’s population is over 60, increasing the prevalence of age-related macular degeneration. Dry AMD accounts for 80-90% of AMD cases, while wet AMD is 10-20% of cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late stage dry AMD). Wet AMD is caused by blood vessels that leak in the retina. These abnormal blood vessels may leak fluids or blood into the back of the eye. Curative Biotech will reformulate metformin to treat intermediate dry AMD and Geographic Atrophy for the first indications. Development to be led by the lead inventor on the NEI Patents, Dr. Kapil Bharti. Curative is in negotiations with NEI to conduct the first clinical trial. This product may be eligible for 505(b)(2) treatment as a reformulation of an already approved drug. The global age-related macular degeneration (AMD) market is expected to attain a value of $8.9 billion by 2022 Stargardt DiseaseStargardt disease is a type of inherited age-related macular degeneration that causes vision loss in children or young adults.The retina contains light-sensing cells called photoreceptors, which include rods and cones. Rods are in the outer retina and help people when lighting is dim and dark. Cones are in the macula and help people see intricate visual detail and color. Both cones and rods negatively affected in Stargardt disease, cones are more strongly impacted in people who have Stargardt disease. The Global Stargardt Disease Therapeutics Market is estimated to be valued at US$ 213.5 million in 2023 and is expected to exhibit a CAGR of 31.7% during the forecast period (2023 - 2028). Retinitis PigmentosaRetinitis pigmentosa (RP) is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. People with RP experience a gradual decline in their vision, because photoreceptors degenerate. Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Retinitis Pigmentosa (RP), an acquired retinal condition that causes retinal depletion, is an uncommon illness. Its underlying manifestations are decreased night vision along with loss of fringe vision. It slowly causes visual impairment. There is no conclusive remedy for retinitis pigmentosa. Hence medical institutions and various research and development centers are researching to develop a full proof cure for this disease which is boosting the growth of global retinitis pigmentosa market. ChoroideremiaChoroideremia is a hereditary degeneration of the retina in males that causes a gradual loss of vision. It starts in early childhood with night-blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. The lack of a functional protein in the retina causes cell death that is followed by the gradual deterioration of the retinal pigment epithelium, photoreceptors, and the choroid. Choroideremia results in progressive loss of vision and is more prominent in males. The first symptom of choroideremia is usually night blindness that occurs at an early stage. Global Choroideremia Treatment market is expected to account for $4.3 Billion by 2028 Late Onset Retinal DegenerationLate-onset retinal degeneration occurs in adulthood and is an inherited retinal dystrophy. It leads to central vision loss. https://www.sciencedaily.com/releases/2021/12/211209133927.htm Diabetic RetinopathyDiabetic retinopathy is the leading cause of blindness in adults. It is a complication of diabetes that causes damage to the blood vessels of the retina. At first, diabetic retinopathy may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The global diabetic retinopathy market reached a value of US$ 7.64 Billion in 2020. and is expected to register a CAGR of 7.6% over the forecast period. Market growth can be primarily attributed to increased funding by regulatory bodies for researching ocular disorders. REFERENCE LINK: https://curativebiotech.com/pipeline |
From 1990 to 2017, worked at National Cancer Insitute of the NIH. Since 2017 Director of Center for Antibody Therapeutics at University of Pittsburgh. Dr. Dimitrov’s major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies in different formats including engineered antibody domains, chimeric antigen receptors, bispecific antibodies and antibody drug conjugates. He has authored or coauthored more than 370 articles, several books, and is the inventor or coinventor of more than 100 inventions, patent applications or patents. Dr. Dimitrov is the lead inventor on the Antibody Drug Conjugate patent exclusively licensed to Curative Biotech from the National Cancer Institute to treat glioblastoma.
Currently President of Sohn Health Strategies and Adjunct Professor at the University of California, San Francisco.
Dr. Sohn has deep biopharmaceutical industry knowledge with over thirty (30) years of U.S. and global experience with expertise in the development and introduction of new medicines for patients and diseases with significant unmet needs. Her skill sets include strategic product development, business development and the introduction of new vaccines, pharmaceutical products and consumer healthcare brands.
Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee. Subsequently, she led the US commercialization of the company’s largest CNS product. Dr. Sohn later became senior vice president, Worldwide Business Development and a member of the global executive committee at GlaxoSmithKline Consumer Healthcare where she led U.S. and global transactions, including the $1.3 billion acquisition and integration of Block Drug and the $566 million acquisition of CNS, Inc.
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits.
Paul Michaels, Chairman and President of Curative Biotechnology, said, "We are pleased to announce the successful completion of these important studies, outlined in our Pre IND meeting with the FDA. We are now able to move on to preparing the Company's first IND application to move our Metformin reformulation into a clinical trial to treat Intermediate Dry Age-Related Macular Degeneration (AMD) and Geographical Atrophy (GA) resulting from AMD."
Michaels continued, "Both Dry AMD and GA are currently unmet medical needs with no FDA approved efficacious treatment options. As previously announced, we will be conducting the first in human study under a CRADA (Cooperative Research and Development Agreement) with the National Eye Institute of the National Institutes of Health, in Bethesda Maryland."
About Macular Degeneration (AMD)
Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).
About Curative Biotechnology, Inc. http://curativebiotech.com
Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The Company's pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a novel immune therapy to treat rabies and an adjuvant for vaccines. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation is targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
Contact:
Steve Chizzikhttps://www.wsj.com/articles/curative-biotechnology-announces-completion-of-ind-enabling-reformulated-metformin-hcl-eye-drop-study-01672923305
Connectyx (now Curative Botechnology) Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease
Boca Raton, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD).
The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide.
The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.
Research has shown that Metformin, an FDA-approved drug that has been widely used for the treatment of diabetes in the United States since 1995, can activate AMP-activated protein kinase, can reduce vascular endothelial growth factor (VEGF) secretion, and can correct baseline calcium levels in patient RPE cells. The new treatment indications will require reformulating the drug into an eye drop, injectable or other topical delivery method to be able to deliver sufficient drug to the RPE layer to have a therapeutic effect. This reformulated drug should be eligible for a 505(b)(2) accelerated development path. While the field of use covers treating any degenerative eye disease, the Company is targeting Stargardt, a currently untreatable orphan disease that causes vision loss in children, as the first indication for this therapeutic product.
Paul Michaels, Chairman and President of Connectyx, said, “We are pleased to expand our product portfolio with the addition of reformulated and repurposed Metformin, which is the fifth most prescribed drug in the United States. This very promising product adds a second in licensed product from the NIH to our development portfolio. As stated above, we believe our Metformin reformulation may show efficacy in treating a wide range of RD diseases that cause vision loss. We are focused on developing disease modifying therapeutics to meet the unmet needs of patients. The Company anticipates being prepared for human testing of this reformulation by third quarter of 2022.”
About Age-Related Macular Degeneration, Stargardt Disease, Retinitis Pigmentosa and Choroideremia
AMD is the leading cause of vision loss in people ages 60+. It destroys a patient’s sharp, central vision. Stargardt disease is a type of AMD that causes vision loss in children or young adults. Retinitis pigmentosa is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. Choroideremia is a hereditary retinal degeneration that causes a gradual loss of vision. It starts in early childhood with night blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. Diabetic retinopathy is the leading cause of blindness in adults. Diabetes harms blood vessels inside the eye by weakening them so they leak fluid into the retina, which can damage areas of the retina, causing blurry, distorted vision.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |